ArticleGynecologic oncology reports2026
Ecthyma gangrenosum in a patient with metastatic leiomyosarcoma undergoing chemotherapy: a case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ecthyma gangrenosum (EG) is a rare necrotizing skin infection most commonly associated with Case presentation: A 40 year-old patient with metastatic leiomyosarcoma presented two-weeks after initiating chemotherapy with multiple necrotic vulvar lesions with an erythematous rim, characteristic of EG. She had no systemic symptoms. She was treated empirically with ciprofloxacin and wound cultures confirmed Conclusion: This represents the second reported case of EG in a patient with gynecologic malignancy. It highlights that EG may present without systemic symptoms, even in high-risk neutropenic patients, and underscores the importance of early detection and antipseudomonal antibiotic initiation to prevent adverse outcomes associated with EG in vulnerable oncologic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.